Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Inclusion Criteria

• •Male or female participants 18 years of age or older at the time of signing informed consent
• •Participants who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements prior to study entry
• •Central histologic confirmation of high-grade non-muscle invasive CIS (± Ta/T1) with active disease
• •Participants who are BCG naive, or participants who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis (Cohort A). Participants with CIS (± Ta/T1) who are BCG unresponsive.